Novavax Inc
Q2 2026 Earnings
Market Reaction
Did NVAX Beat Earnings? Q2 2026 Results
Novavax delivered a cleaner-than-expected second quarter, beating both top and bottom lines even as the headline revenue comparison looked severe against a year-ago period bloated by one-time milestone payments. The company posted Q2 2026 revenue of $56.70 million, ahead of the $53.30 million consensus by 6.38%, while its GAAP diluted loss per share of $0.32 came in 16.58% better than the $0.38 analysts had penciled in. The steep 76.3% year-over-year revenue decline was largely a base-period distortion; Q2 2025 had included $202 million in Sanofi milestone and amendment payments that did not recur. Underneath that noise, product sales rose 76% to $18.85 million on stronger Matrix-M adjuvant demand, and operating expenses continued to fall as Sanofi absorbed commercial activities. Investors focused on the strategic transition toward licensing had reason for cautious optimism, with Novavax nudging its full-year Adjusted Total Revenue guidance to $235 million to $275 million and two potentially sizable Sanofi milestones, worth $125 million and $75 million respectively, still on the horizon.
- Product sales grew 76% YoY driven by higher Matrix-M adjuvant demand and sales to license partners
- Total revenue declined 76% due to absence of $202 million in prior-year milestone and amendment payments
- SG&A expenses decreased 39% from transition of commercial activities to Sanofi and cost reduction program
- Non-GAAP R&D expenses declined 34% due to ongoing cost reduction program and streamlining operations
“We're encouraged by the momentum we're seeing across our business as we continue to advance our strategy. As we enter the second half of 2026 and prepare for next year, we believe we are well positioned to deliver several important partner milestones while we advance our internal R&D programs and progress our MTA collaborations. This continued progress reinforces our confidence in our strategy and the potential to drive vaccine innovation to create meaningful value for our shareholders.”
Novavax CEO, on the earnings call
Forward Guidance & Outlook
Novavax raised its full-year 2026 Adjusted Total Revenue framework to $235–$275 million (from $230–$270 million previously), comprising Nuvaxovid Product Sales of $35–$45 million, Adjusted Supply Sales of $45–$55 million (raised from $40–$50 million), and Adjusted Licensing, Royalties and Other Revenue of $155–$175 million. GAAP Combined R&D and SG&A expense guidance improved by $10 million at midpoint to $370–$410 million. Non-GAAP Combined R&D and SG&A Expenses maintained at $310–$340 million. Sanofi Supply Sales, Royalties and Milestones are excluded from the framework as they depend on Sanofi forecasts. The company is eligible for up to $350 million in Phase 3 development and commercial launch milestones from Sanofi CIC products, plus up to $200 million in launch and sales milestones per new Matrix-M vaccine with mid-single digit royalties for 20 years. Manufacturing technology transfer completion in mid-2027 would trigger a $75 million milestone, and initiation of the Sanofi Phase 3 CIC trial would trigger a $125 million milestone.
NVAX YoY Financials
NVAX Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.